Dovitinib Lactate

多维替尼乳酸盐

Report date: 2025/12/31 20:01:55
NME

Base Information

Drug NameDovitinib Lactate
Drug Alias NameDovitinibum多威替尼Dovitinib多韦替尼多韦替尼乳酸盐 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonists +[10] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorPlatelet-derived growth factor receptor beta +[10] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursvon Hippel-Lindau Disease +[36] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaPending
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGeorgetown UniversityThe University Of California DavisOncoheroes Biosciences Inc +[15] 
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerSolid tumoursvon Hippel-Lindau Disease +[36] 

Other Information

ATC CodeN/A
Related LinksKEGG